General
Preferred name
Mitapivat
Synonyms
PKR-IN-1 ()
Mitapivat ()
AG-348 ()
MITAPIVAT SULFATE ()
Mitapivat hemisulfate sesquihydrate ()
Pyrukynd ()
AG-348 HEMISULFATE SESQUIHYDRATE ()
AG-348 sulfate hydrate ()
Mitapivat sulfate hydrate ()
P&D ID
PD016563
CAS
1260075-17-9
2151847-10-6
Tags
available
drug
Approved by
EMA
FDA
First approval
2022
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Thalassemia
familial hemolytic anemia
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mitapivat (AG-348) is a first-in-class, small molecule allosteric activator of the pyruvate kinases. It activates the PK isoform that is found in erythrocytes (PKR protein that is expressed from the PKLR gene) and the embryonic PKM2 isoform (expressed from the PKM gene) that is only expressed by cancer cells in adult tissues. Mitapivat was developed by Agios Pharmaceuticals as a novel therapy for diseases of red blood cells that are associated with inherited PKR deficiency , and for potential in cancer therapy via activation of PKM2. Activation of PK in red cells increases hemoglobin levels . The active drug is the sulfate hydrate (PubChem CID 134693700). We show the structure for the parent molecule as described by its INN.
(GtoPdb)
DESCRIPTION
Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency[1][2][3].
PRICE
118
PRICE
942
DESCRIPTION
Mitapivat sulfate hydrate (AG 348 sulfate hydrate) is an erythrocyte pyruvate kinase (PK) allosteric activator. It enhances enzyme activity, protein stability, and ATP levels in various PKLR genotypes and can be used in pyruvate kinase deficiency research.
DESCRIPTION
Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
450.17
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
3
cLogP
3.2
TPSA
82.61
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PKM2
pyruvate kinase
PKM2 activator
PKM
MOA
pyruvate kinase isozyme activator
Pathway
Metabolic Enzyme/Protease
Metabolism
Source data
